Skip to main content Skip to section navigation Skip to footer

Lucid Diagnostics Inc.

  • Investors
  • Company

    • About Us
    • Leadership
    • Medical Advisory Board
    • Careers
  • Products

    • EsoCheck
    • EsoGuard
  • Clinical

    • BETRNet
    • References
  • Investor Relations
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity Matrix
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 11, 2022 4:00pm EDT

Lucid Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results

May 09, 2022 8:25am EDT

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans

Apr 28, 2022 4:05pm EDT

PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit

Apr 25, 2022 8:25am EDT

Lucid Diagnostics to Hold a Business Update Conference Call on May 11, 2022

Apr 04, 2022 8:25am EDT

Lucid Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination

Mar 30, 2022 8:25am EDT

Lucid Diagnostics to Participate in the Needham 21st Annual Healthcare Conference

Mar 28, 2022 4:47pm EDT

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

Mar 24, 2022 8:25am EDT

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study

Mar 23, 2022 8:25am EDT

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

Mar 07, 2022 8:30am EST

Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
rss_feedNews RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

One Grand Central Place, Suite 4600
New York, NY 10165

Email: info@LucidDX.com

212-949-4319

  • White Twitter Icon
  • White LinkedIn Icon
  • ©2023 Lucid Diagnostics Inc. All Rights Reserved.
  • Privacy Policy